StocksC › CLSD

Clearside Biomedical, Inc. (CLSD) — Earnings Call X-Ray

Our AI read all 28 of CLSD's earnings calls (2017–2024) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q1 2024 · sign up to see
Previous Call Grade
C
Q4 2023
Expected Move
🔒
next 45 days · members
Calls Analyzed
28
2017–2024
Avg Candor
6.3/9
evasion 3.2/9
High CandorPromotional ToneCritic AmmunitionUnderused Fixed CostsReads RehearsedQuestion Left Hanging

Call-by-call analysis

🔒 Q1 2024 earnings call 2024-05-09 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q1 2024 call grade is ready
The full 37-point AI read of CLSD's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

C Q4 2023 earnings call 2024-03-13 move ±21.1%

Management held guidance steady. The delivery was unusually candid, relaxed under questioning, promotional in tone.

Guidance: maintainedPricing: stable 3 analysts · 5 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsed
Candor 7/9
Specificity 6/9
Evasion 2/9
Confidence 8/9
Uncertainty 4/9
Promotion 7/9
Stress 1/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C Q3 2023 earnings call 2023-11-13

Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.

4 analysts · 6 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 7/9
Uncertainty 5/9
Promotion 7/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q2 2023 earnings call 2023-08-14 move ±14.6%

Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.

6 analysts · 14 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 5/9
Specificity 7/9
Evasion 4/9
Confidence 8/9
Uncertainty 4/9
Promotion 7/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q1 2023 earnings call 2023-05-11 move ±13.5%

Management gave no formal guidance. The delivery was rich in specifics.

5 analysts · 10 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 7/9
Uncertainty 4/9
Promotion 6/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
From the research question bank
1 more research questions answered NO

C Q4 2022 earnings call 2023-03-09 move ±17.5%

Management held guidance steady.

Guidance: maintainedHeadcount: flat 5 analysts · 7 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsed
Candor 6/9
Specificity 6/9
Evasion 3/9
Confidence 7/9
Uncertainty 4/9
Promotion 6/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C Q3 2022 earnings call 2022-11-09 move ±15.1%

Management gave no formal guidance. The delivery was unusually candid, rich in specifics.

6 analysts · 12 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsed
Candor 7/9
Specificity 8/9
Evasion 4/9
Confidence 8/9
Uncertainty 5/9
Promotion 6/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
From the research question bank
331 more research questions answered NO

D Q2 2022 earnings call 2022-08-09 move ±12%

Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.

Headcount: growing 5 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 7/9
Uncertainty 5/9
Promotion 7/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q1 2022 2022-05-11 C noneunclearunclear 7/9 4/9
Q4 2021 2022-03-10 B noneunclearunclear 7/9 2/9
Q3 2021 2021-11-10 B raisedstableunclear 7/9 3/9
Q2 2021 2021-08-10 D maintainedunclearunclear 6/9 4/9
Q1 2021 2021-05-17 C+ noneunclearunclear 6/9 2/9
Q4 2020 2021-03-10 C noneunclearunclear 7/9 2/9
Q3 2020 2020-11-10 C maintainedunclearunclear 6/9 2/9
Q2 2020 2020-08-10 D noneunclearunclear 7/9 3/9
Q4 2019 2020-03-11 C maintainedstableunclear 7/9 3/9
Q3 2019 2019-11-10 C+ noneunclearcontracting 7/9 2/9
Q2 2019 2019-08-07 D noneunclearcontracting 7/9 4/9
Q1 2019 2019-05-08 D noneunclearcontracting 6/9 4/9
Q4 2018 2019-03-12 C noneunclearcontracting 6/9 4/9
Q3 2018 2018-11-10 C noneunclearcontracting 7/9 4/9
Q2 2018 2018-08-08 C maintainedunclearcontracting 6/9 4/9
Q1 2018 2018-05-12 C+ maintainedunclearunclear 6/9 3/9
Q4 2017 2018-03-14 C noneunclearcontracting 6/9 3/9
Q3 2017 2017-11-08 D noneunclearcontracting 5/9 4/9
Q2 2017 2017-08-09 D noneunclearcontracting 6/9 3/9
Q1 2017 2017-05-10 C noneunclearunclear 6/9 4/9

Research question bank — earlier calls

During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of CLSD's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.

D Q2 2017 earnings call 2017-08-09

1 more research questions answered NO

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAP · Advance Auto Parts, Inc.ABCAF · Athabasca Minerals, Inc.ABDC · Alcentra Capital'sABMD · Abiomed, Inc.ABNRY · ABN AMRO Bank N.V.ABOS · Acumen Pharmaceuticals,

CLS   All “C” companies    CLSH

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.